Showing 2791-2800 of 5646 results for "".
- Acucela Signs Agreement to Develop a Compact OCT for NASA’s Deep Space Missionshttps://modernod.com/news/acucela-signs-agreement-to-develop-a-compact-oct-for-nasas-deep-space-missions/2476385/Acucela announced that the company signed the agreement with the Translational Research Institute for Space Health (TRISH) to develop a compact OCT device for NASA’s Deep Space missions. Approximately 63% of long-duration spaceflight crewmembers present with one or more signs of Spacefligh
- Study Demonstrates Long-Term IOP Reduction with the OMNI Surgical System Predicate Device (TRAB 360) in MIGShttps://modernod.com/news/clinical-study-demonstrates-long-term-iop-reduction-with-the-omni-surgical-system-predicate-device-trab-360-in-migs/2476378/A new, single-center retrospective study of glaucoma surgery patients published in the January 2019 issue of Clinical Ophthalmology shows that ab-interno trabeculotomy using one of Sight Sciences’ OMNI Surgical System’s Predicate Devices (TRAB 360)
- EyePoint Pharmaceuticals Announces US Commercial Launch of Dexycuhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-us-commercial-launch-of-dexycu/2476370/EyePoint Pharmaceuticals announced that it has commercially launched Dexycu (dexamethasone intraocular suspension) 9% in the United States. Dexycu is the first and only FDA approved intraocular steroid for the treatment of postoperative inflammation and is administered as a single dose at the end
- Q Biomed Licenses Novel Biomarker for Monitoring Glaucoma Severity and Progression From Washington Universityhttps://modernod.com/news/q-biomed-licenses-novel-biomarker-for-monitoring-glaucoma-severity-and-progression-from-washington-university/2476369/Q BioMed has announced it has exercised its option to exclusively license GDF15, a diagnostic marker for determining the severity of glaucoma using the expression levels of Growth Differentiation Factor 15 (GDF15) from the Washington University in St. Louis. Determining the severity
- Major League Soccer All-Star Alecko Eskandarian to Speak at Annual NORA Conferencehttps://modernod.com/news/major-league-soccer-all-star-alecko-eskandarian-to-speak-at-annual-nora-conference/2476364/Two-time Major League Soccer (MLS) All-Star Alecko Eskandarian will be the key-note speaker at the Neuro-Optometric Rehabilitation Association, International (NORA) 28th annual General Conference (September 21-22) at the Embassy Suites by Hilton Scottsdale Resorts, Scottsdale, Arizona.
- Telemedicine Eye Screenings Help Detect Glaucomahttps://modernod.com/news/telemedicine-eye-screenings-help-detect-glaucoma/2476356/A low-cost program using technicians to conduct telemedicine eye screenings can help detect glaucoma in underserved populations, according to new research, as reported by Reuters. The study targeted high-risk individuals in poorer a
- Myco Industries Debuts AB Max Advanced for Treatment of Anterior Blepharitishttps://modernod.com/news/myco-industries-debuts-ab-max-advanced-for-treatment-of-anterior-blepharitis/2476354/Myco Industries released AB MAX, a new treatment for anterior blepharitis. The AB MAX is an adapter that allows eye care professionals to increase the functionality of their Algerbrush by converting it into a multi-purpose device for treatment of the same conditions as a standard Algerbrush, as w
- FDA Grants Breakthrough Device Designation to Concussion Assessment Devicehttps://modernod.com/news/fda-grants-breakthrough-device-designation-to-concussion-assessment-device/2476351/SyncThink announced that the FDA has granted Breakthrough Device Designation to EYE-SYNC, an objective eye-tracking platform. The EYE-SYNC platform is used to assist clinicians in evaluating visual impairments, monitor recovery, and support the rehabilitation of ocular-motor and ocular-vestibular
- Novartis Issues Summary Financial Information for the Alcon Eye Care Business Ahead of Shareholder Votehttps://modernod.com/news/novartis-issues-summary-financial-information-for-the-alcon-eye-care-business-ahead-of-shareholder-vote/2476260/Novartis today published certain key financial information for the Alcon eye care business covering the full year 2018 ahead of a vote on the proposed 100% spin-off of Alcon at the Novartis Annual General Meeting of Shareholders (AGM) on February 28, 2019. The issuance of the short form fi
- Ziemer USA Names Brad Hurt Vice President of Business Developmenthttps://modernod.com/news/ziemer-usa-names-brad-hurt-vice-president-of-business-development/2476263/Ziemer USA announced the appointment of Brad Hurt to its executive US leadership team as Vice President of Business Development. Mr. Hurt joins Ziemer USA from Bausch + Lomb Surgical, where he was most recently Vice President of US Surgical Sales. “I couldn’t be more excited to join the Zi